• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    The Analyst Verdict: Absci In The Eyes Of 6 Experts

    5/15/24 9:00:39 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $ABSI alert in real time by email

    Across the recent three months, 6 analysts have shared their insights on Absci (NASDAQ:ABSI), expressing a variety of opinions spanning from bullish to bearish.

    Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.

    Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
    Total Ratings 4 2 0 0 0
    Last 30D 1 0 0 0 0
    1M Ago 0 0 0 0 0
    2M Ago 2 0 0 0 0
    3M Ago 1 2 0 0 0

    In the assessment of 12-month price targets, analysts unveil insights for Absci, presenting an average target of $8.83, a high estimate of $13.00, and a low estimate of $7.00. This current average reflects an increase of 26.14% from the previous average price target of $7.00.

    price target chart

    Interpreting Analyst Ratings: A Closer Look

    A clear picture of Absci's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

    Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target
    Swayampakula Ramakanth HC Wainwright & Co. Maintains Buy $7.00 -
    Robyn Karnauskas Truist Securities Maintains Buy $9.00 $9.00
    Swayampakula Ramakanth HC Wainwright & Co. Maintains Buy $7.00 -
    George Farmer Scotiabank Announces Sector Outperform $13.00 -
    Robyn Karnauskas Truist Securities Announces Buy $9.00 -
    Scott Schoenhaus Keybanc Raises Overweight $8.00 $5.00

    Key Insights:

    • Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Absci. This information offers a snapshot of how analysts perceive the current state of the company.
    • Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Absci compared to the broader market.
    • Price Targets: Delving into movements, analysts provide estimates for the future value of Absci's stock. This analysis reveals shifts in analysts' expectations over time.

    Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Absci's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.

    Stay up to date on Absci analyst ratings.

    If you are interested in following small-cap stock news and performance you can start by tracking it here.

    Discovering Absci: A Closer Look

    Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.

    Absci's Financial Performance

    Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.

    Revenue Challenges: Absci's revenue growth over 3 months faced difficulties. As of 31 December, 2023, the company experienced a decline of approximately -78.29%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.

    Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -6965.98%, the company showcases strong profitability and effective cost control.

    Return on Equity (ROE): Absci's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -12.64%, the company may face hurdles in achieving optimal financial returns.

    Return on Assets (ROA): Absci's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -10.38%, the company may face hurdles in achieving optimal financial returns.

    Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.09.

    The Significance of Analyst Ratings Explained

    Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.

    Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ABSI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABSI

    DatePrice TargetRatingAnalyst
    1/8/2026$4.32Overweight → Equal-Weight
    Morgan Stanley
    10/2/2025Overweight
    Analyst
    7/3/2025$7.00Overweight
    Morgan Stanley
    1/22/2025$9.00Buy
    Needham
    10/2/2024$10.00Buy
    Guggenheim
    7/3/2024$7.00Overweight
    Morgan Stanley
    3/14/2024$13.00Sector Outperform
    Scotiabank
    12/5/2023$3.00Overweight
    KeyBanc Capital Markets
    More analyst ratings

    $ABSI
    SEC Filings

    View All

    Absci Corporation filed SEC Form 8-K: Leadership Update, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Absci Corp (0001672688) (Filer)

    3/6/26 4:20:32 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SCHEDULE 13G filed by Absci Corporation

    SCHEDULE 13G - Absci Corp (0001672688) (Subject)

    1/30/26 12:56:05 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Absci Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Absci Corp (0001672688) (Filer)

    1/14/26 5:27:05 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ABSI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Pangalos Menelas N bought $205,760 worth of shares (75,095 units at $2.74), increasing direct ownership by 66% to 189,055 units (SEC Form 4)

    4 - Absci Corp (0001672688) (Issuer)

    3/3/26 4:13:20 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Director Van Houten Frans bought $148,800 worth of shares (40,000 units at $3.72), increasing direct ownership by 172% to 63,320 units (SEC Form 4)

    4 - Absci Corp (0001672688) (Issuer)

    12/9/25 4:04:20 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Director Pangalos Menelas N bought $254,788 worth of shares (95,785 units at $2.66), increasing direct ownership by 527% to 113,960 units (SEC Form 4)

    4 - Absci Corp (0001672688) (Issuer)

    9/24/25 4:03:44 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ABSI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    VANCOUVER, Wash. and NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced that on March 3, 2026, the company granted a non-statutory stock option to purchase an aggregate of 650,000 shares of its common stock to Dr. Ransi Somaratne in connection with his employment as Absci's Chief Medical Officer. The inducement grant was previously approved by the Compensation Committee of Absci's Board of Directors pursuant to Absci's 2023 Inducement Plan (the "Inducement Plan"), and is being made as an inducement material to the new employee's acceptance o

    3/6/26 4:05:00 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Absci Strengthens Clinical Leadership with Appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer

    Former Vertex executive to spearhead the clinical development of Absci's expanding AI-designed therapeutics pipeline Chief Innovation Officer Andreas Busch to retire March 31, 2026 and will continue to co-chair Absci's Scientific Advisory Board VANCOUVER, Wash. and NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer. Dr. Somaratne will spearhead the clinical development strategy and execution for Absci's expanding pipeline of AI-designed therapeutics. Dr. Somarat

    3/3/26 8:00:00 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Absci to Report Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results on March 24, 2026

    VANCOUVER, Wash. and NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will report business updates and financial and operating results for the fourth quarter and full year 2025 after market close on Tuesday, March 24, 2026. Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its business developments, financial and operating results, and outlook. Live audio of the webcast will be available on the company's investor relations website at: investors

    2/24/26 8:00:00 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ABSI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Absci Corporation downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Absci Corporation from Overweight to Equal-Weight and set a new price target of $4.32

    1/8/26 8:35:39 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Analyst initiated coverage on Absci Corporation

    Analyst initiated coverage of Absci Corporation with a rating of Overweight

    10/2/25 8:38:38 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Morgan Stanley resumed coverage on Absci Corporation with a new price target

    Morgan Stanley resumed coverage of Absci Corporation with a rating of Overweight and set a new price target of $7.00

    7/3/25 7:48:59 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ABSI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Pangalos Menelas N was granted 5,800 shares, increasing direct ownership by 3% to 194,855 units (SEC Form 4)

    4 - Absci Corp (0001672688) (Issuer)

    3/5/26 6:56:53 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Chief Legal Officer Walker Shelby J. covered exercise/tax liability with 9,825 shares and was granted 90,300 shares, increasing direct ownership by 136% to 139,775 units (SEC Form 4)

    4 - Absci Corp (0001672688) (Issuer)

    3/4/26 9:14:12 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Chief Executive Officer Mcclain Sean was granted 406,200 shares and covered exercise/tax liability with 25,316 shares, increasing direct ownership by 5% to 8,715,451 units (SEC Form 4)

    4 - Absci Corp (0001672688) (Issuer)

    3/4/26 9:05:13 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ABSI
    Financials

    Live finance-specific insights

    View All

    Absci to Report Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results on March 24, 2026

    VANCOUVER, Wash. and NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will report business updates and financial and operating results for the fourth quarter and full year 2025 after market close on Tuesday, March 24, 2026. Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its business developments, financial and operating results, and outlook. Live audio of the webcast will be available on the company's investor relations website at: investors

    2/24/26 8:00:00 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Absci Reports Business Updates and Third Quarter 2025 Financial and Operating Results

    Reported interim results for Phase 1 trial for ABS-101 (anti-TL1A) On track to initiate Ph1/2a trial for ABS-201 (anti-PRLR for androgenetic alopecia) in December; hosting KOL seminar on December 11 Expanding ABS-201 strategy to pursue endometriosis as additional indication; anticipate initiation of Phase 2 clinical trial in the fourth quarter of 2026 Cash, cash equivalents, and marketable securities sufficient to fund operations into the first half of 2028 VANCOUVER, Wash. and NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today reported financial and operat

    11/12/25 4:05:00 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Absci to Report Business Updates and Third Quarter 2025 Financial and Operating Results on November 12, 2025

    VANCOUVER, Wash. and NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Absci (NASDAQ:ABSI), a clinical-stage biotech company advancing breakthrough therapeutics with generative AI, today announced the company will report business updates and financial and operating results for the third quarter 2025 after market close on Wednesday, November 12, 2025. Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its business developments, financial and operating results, and outlook. Live audio of the webcast will be available on the company's investor relations website at: investors.absci.com. The webcast will be archived

    10/29/25 4:05:00 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ABSI
    Leadership Updates

    Live Leadership Updates

    View All

    Absci Strengthens Clinical Leadership with Appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer

    Former Vertex executive to spearhead the clinical development of Absci's expanding AI-designed therapeutics pipeline Chief Innovation Officer Andreas Busch to retire March 31, 2026 and will continue to co-chair Absci's Scientific Advisory Board VANCOUVER, Wash. and NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer. Dr. Somaratne will spearhead the clinical development strategy and execution for Absci's expanding pipeline of AI-designed therapeutics. Dr. Somarat

    3/3/26 8:00:00 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Absci Appoints Biopharma Leader Mary Szela to Board of Directors

    VANCOUVER, Wash., July 07, 2025 (GLOBE NEWSWIRE) -- Absci (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the appointment of veteran biopharmaceutical executive Mary Szela to its Board of Directors. With decades of R&D and commercial leadership experience, Ms. Szela has played pivotal roles in advancing transformative therapies, notably guiding the global launch and expansion of Humira® into multiple indications during her tenure at Abbott Laboratories. "Mary has been a driving force behind the development of one of the most successful therapies in the industry, bringing a rare and invaluable bread

    7/7/25 8:00:00 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Absci Appoints Professor Sir Mene Pangalos to its Board of Directors

    Sir Pangalos is a distinguished biopharmaceutical executive who led BioPharmaceuticals R&D at AstraZeneca.  In addition to joining Absci's Board, Sir Pangalos will co-chair Absci's Scientific Advisory Board. VANCOUVER, Wash., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Absci (NASDAQ:ABSI), a generative AI drug creation company, today announced the appointment of seasoned R&D executive Professor Sir Menelas "Mene" Pangalos to its Board of Directors and as co-chair of Absci's Scientific Advisory Board. Sir Pangalos was the Executive Vice President of BioPharmaceuticals R&D at AstraZeneca. He joins Absci as the company scales its AI-enabled portfolio of partnered and wholly-owned assets. "The rapid e

    1/10/24 7:30:00 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ABSI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Absci Corporation

    SC 13G - Absci Corp (0001672688) (Subject)

    11/14/24 4:02:50 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Amendment: SEC Form SC 13G/A filed by Absci Corporation

    SC 13G/A - Absci Corp (0001672688) (Subject)

    11/12/24 9:50:12 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13D/A filed by Absci Corporation (Amendment)

    SC 13D/A - Absci Corp (0001672688) (Subject)

    3/5/24 5:15:30 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care